3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Gynecologic
1
Dermatologic
1
Conditions
Keratosis, Actinic
7
Melanoma
3
Uveal Melanoma
1
Squamous Intraepithelial Lesions
1
Skin Neoplasms
1
Ovarian Neoplasms
1
Nonmelanoma Skin Cancers
1
Neoplasm Metastasis
1
Lymphoma, T-Cell
1
Carcinoma, Squamous Cell
1
Carcinoma, Basal Cell
1
Basal Cell Nevus Syndrome
1
Interventions
pembrolizumab
28
Cyclophosphamide
14
Nivolumab
13
Paclitaxel
7
fludarabine
6
Specimen Handling
5
aldesleukin
4
Taxes
4
Ipilimumab
4
Interleukin-2
4
Gemcitabine
4
Drug Therapy
4
Docetaxel
4
Carboplatin
4
Bevacizumab
4
poly ICLC
3
liposomal doxorubicin
3
epacadostat
3
cobimetinib
3
cemiplimab
3
Magnetic Resonance Spectroscopy
3
Injections
3
Cisplatin
3
veliparib
2
ulixertinib
2
sargramostim
2
pertuzumab
2
pegilodecakin
2
pazopanib
2
osimertinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Solutions
×
Dermatologic
×
Clear all
NCT04752826
2026-02-18
MK-3475-D20
BioInvent International AB
Phase 1/2
Recruiting
176 enrolled